Acquisition by Branislav Vajdic of 10000 shares of Heartbeam subject to Rule 16b-3
| BEAT Stock | USD 1.00 0.02 1.96% |
Slightly above 62% of Heartbeam's investor base is looking to short. The analysis of overall sentiment of trading Heartbeam stock suggests that many investors are alarmed at this time. Heartbeam's investing sentiment can be driven by a variety of factors including economic data, Heartbeam's earnings reports, geopolitical events, and overall market trends.
Heartbeam | Build AI portfolio with Heartbeam Stock |
Filed transaction by Heartbeam Officer Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Heartbeam Fundamental Analysis
We analyze Heartbeam's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Heartbeam using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Heartbeam based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Heartbeam is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Heartbeam Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Heartbeam stock to make a market-neutral strategy. Peer analysis of Heartbeam could also be used in its relative valuation, which is a method of valuing Heartbeam by comparing valuation metrics with similar companies.
Peers
Heartbeam Related Equities
| ATRC | AtriCure | 3.27 | ||||
| BFRG | Bullfrog | 3.08 | ||||
| CTEV | Claritev | 2.16 | ||||
| SUPN | Supernus Pharmaceuticals | 1.30 | ||||
| IRTC | IRhythm Technologies | 0.01 | ||||
| CORT | Corcept Therapeutics | 1.84 | ||||
| AAOI | Applied Opt | 3.47 | ||||
| FOXO | FOXO Technologies | 6.67 | ||||
| HCTI | Healthcare Triangle | 20.16 |
Additional Tools for Heartbeam Stock Analysis
When running Heartbeam's price analysis, check to measure Heartbeam's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heartbeam is operating at the current time. Most of Heartbeam's value examination focuses on studying past and present price action to predict the probability of Heartbeam's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heartbeam's price. Additionally, you may evaluate how the addition of Heartbeam to your portfolios can decrease your overall portfolio volatility.